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Lantibiotics are ribosomally synthesized and post-
translationally modified antimicrobial peptides. The
recently discovered lantibiotic epilancin 15X
produced by Staphylococcus epidermidis 15X154
contains an unusual N-terminal lactate group. To
understand its biosynthesis, the epilancin 15X
biosynthetic gene cluster was identified. The
N-terminal lactate is produced by dehydration of
a serine residue in the first position of the core
peptide by ElxB, followed by proteolytic removal of
the leader peptide by ElxP and hydrolysis of the re-
sulting new N-terminal dehydroalanine. The pyruvate
group thus formed is reduced to lactate by an
NADPH-dependent oxidoreductase designated
ElxO. The enzymatic activity of ElxB, ElxP, and
ElxO were investigated in vitro or in vivo and the
importance of the N-terminal modification for
peptide stability against bacterial aminopeptidases
was assessed.INTRODUCTION
Bacterial resistance to known classes of antibacterial agents
has been rising at an alarming rate. Currently, 60%–70% of all
Staphylococcus aureus strains isolated in hospitals are multi-
drug resistant (Taubes, 2008). In order to prevent potential
epidemic outbreaks of infectious diseases, new antibacterial
drugs not affected by existing resistance mechanisms are
much needed. Lantibiotics are ribosomally synthesized and
posttranslationally modified polycyclic peptides that contain
thioether crosslinks and that demonstrate promising activity
against pathogenic bacteria (Willey and van der Donk, 2007).
Nisin (Figure 1), the most studied lantibiotic, has been used as
a food preservative during the last 40 years in more than 80
countries without the development of stable resistance, possibly
as a consequence of its multiple modes of action (Breukink and
de Kruijff, 2006). The N-terminal portion of nisin recognizes the
membrane-bound cell wall precursor lipid II, inhibiting peptido-
glycan biosynthesis (Breukink et al., 1999; Bro¨tz et al., 1998).
Once the molecule is docked to the membrane, the C-terminalChemistry & Biology 18,portion generates stable pores that result in membrane damage
and depolarization (Wiedemann et al., 2001).
The lantibiotic epilancin 15X (Figure 1) was isolated from
Staphylococcus epidermidis 15X154 and is active against
several pathogenic bacteria, including methicillin-resistant
S. aureus and vancomycin-resistant Enterococci, with minimal
inhibitory concentration (MIC) values among the lowest reported
for lantibiotics (Ekkelenkamp et al., 2005; Verhoef et al., 2005).
Epilancin 15X contains one lanthionine (Lan) and two 3-methyl-
lanthionine (MeLan) bridges, one 2,3-dehydroalanine (Dha)
residue, three (Z)-2,3-dehydrobutyrine (Dhb) residues, and an
unusual N-terminal 2-hydroxypropionyl group (lactate; Lac).
The C-terminal B and C rings of epilancin 15X are structurally
similar to the D and E rings of nisin A (Figure 1) that are believed
to be involved in pore formation (Wiedemann et al., 2001).
However, formation of pores would not explain by itself the low
MIC values of epilancin 15X. In the case of nisin, the potent anti-
bacterial activity is a consequence of docking onto lipid II by the
A andB rings (Hsu et al., 2004), which greatly enhances the pore-
forming ability (Breukink et al., 1999). However, epilancin 15X
does not contain the A and B rings found in nisin, and lipid II
does not appear to be a target of epilancin K7 (Figure 1), a struc-
turally closely related analog of epilancin 15X (van deKamp et al.,
1995a, 1995b). Thus, the N-terminal portion of epilancin 15X and
the unusual lactate group may be involved in a currently
unknown alternative mechanism. Indeed, additional posttransla-
tional modifications beyond the Lan or MeLan rings are often
important for biological activity of lantibiotics. In the case of cin-
namycin, a b-hydroxylated aspartate residue and a lysinoalanine
ring are important for recognition of its target (Hosoda et al.,
1996). In another example, the lantibiotic microbisporicin, which
has a very similar ring topology as epidermin, is two orders of
magnitude more potent than the latter compound against
several strains of S. aureus, presumably because of hydroxyl-
ated proline and chlorinated tryptophan residues that are absent
in epidermin (Castiglione et al., 2008). Thus, the N-terminal
lactate group might also be important for the antimicrobial
activity of epilancin 15X.
An N-terminal lactate is also present in epicidin 280 and epi-
lancin K7 (van de Kamp et al., 1995b), but its biosynthetic origin
has not been determined. In the case of epicidin 280, the putative
oxidoreductase EciO may be involved, but this hypothesis has
not been confirmed experimentally (Heidrich et al., 1998). Herein
we report the gene cluster involved in the biosynthesis of
epilancin 15X. Additionally, we demonstrate that ElxO is an857–867, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 857
Figure 1. Structures of the Lantibiotics Epilancin 15X, Nisin A, and Epilancin K7
A previously reported shorthand notation (Chatterjee et al., 2005b) is used. The stereochemical configuration of the N-terminal lactate group in epilancin 15X was
determined in this study.
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Biosynthesis of Epilancin 15XNADP(H)-dependent alcohol dehydrogenase that catalyzes the
conversion of an N-terminal pyruvate to lactate and that the
lactate group plays a protective role against proteolytic degrada-
tion. We also report the in vitro reconstitution of the enzymatic
activity of ElxP, to the best of our knowledge the first such
example for a member of the serine-type lantibiotic proteases.
RESULTS
Cloning and Sequencing of the Epilancin 15X
Biosynthetic Gene Cluster
To identify and sequence the epilancin 15X biosynthetic gene
cluster, a fosmid library of S. epidermidis 15X154 genomic DNA
was constructed in Escherichia coli. The fosmid library was
screenedbyPCRusingdegenerate primers to amplify a fragment
of elxA (the gene encoding the precursor peptide) and elxC (the
gene encoding a lanthionine cyclase). The primers were de-
signed based on the amino acid sequence of epilancin 15X and
conserved nucleotide sequences in the genes encoding the
cyclase enzymes. Two positive clones containing nonoverlap-
ping DNA fragments were isolated and the fosmids858 Chemistry & Biology 18, 857–867, July 29, 2011 ª2011 Elsevier Lwere sequenced using transposon insertions. Specific primers
annealing with regions of S. epidermidis 15X154 genomic DNA
were then used to amplify by PCR a bridging 1.2 kb DNA frag-
ment that was sequenced to obtain the biosynthetic gene cluster
(Figure 2). The open reading frames (ORFs) were analyzed with
the Basic Local Alignment Search Tool (BLAST) (Altschul et al.,
1990), and six ORFs encoding putative proteins with high
sequence identity to enzymes involved in the production and
transport of lantibiotics were identified: elxA, elxB, elxC, elxP,
elxT, and elxO (Table 1 and Figure 2; see Figure S1 available on-
line). Additionally, three geneswith no homology to characterized
lantibiotic genes andpresumably involved in immunitywere iden-
tified and designated as elxI1, elxI2, and elxI3. With the exception
of elxO, the role of the other genes in epilancin 15X biosynthesis
can be predicted based on homology to previously characterized
lantibiotic genes. The gene encoding the precursor peptide elxA
encodes a serine residue at the first position of the core peptide
(the region of the precursor peptide that ismodified to themature
lantibiotic) (Oman and van der Donk, 2010), which corresponds
to lactate in epilancin 15X. Thus, Ser1must be posttranslationally
modified by an undetermined enzyme.td All rights reserved
Figure 2. Epilancin 15X Gene Cluster
For amino acid sequences, see Figure S1.
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Biosynthesis of Epilancin 15XCloning and Overexpression of elxO
To study the role of ElxO, the corresponding gene was cloned
into a pET28b vector to generate pHis6-ElxO, which encodes
an N-terminal hexahistidine fusion protein (His6-ElxO). His6-
ElxO was heterologously produced in E. coli Rosetta 2 cells
and the enzyme was purified by immobilized metal ion-affinity
chromatography (IMAC) with Ni2+, resulting in 60 mg of purified
protein per liter of cell culture. The enzyme migrated as a
protein of approximately 30 kDa by SDS-PAGE analysis, close
to the predicted monomeric molecular weight of His6-ElxO
(29.7 kDa). Native molecular weight analysis using gel-filtration
chromatography showed that His6-ElxO exists as a dimer
(59 kDa, observed).In Vitro Reconstitution of the Enzymatic Activity
of His6-ElxO and Determination of the Stereochemistry
of the Reaction
On the basis of its amino acid sequence (Figure S1D), ElxO is
a member of the short-chain dehydrogenase/reductase (SDR)
superfamily that catalyzes the interconversion of alcohols to
aldehydes or ketones using NAD(P)(H) as a cofactor. Dehydroe-
pilancin 15X, containing an N-terminal pyruvyl group, could
therefore be the substrate for ElxO. Because dehydroepilancin
15X was not available, the small peptide AAIVK was synthesized
by Fmoc-based solid-phase peptide synthesis (SPPS) followed
by coupling of pyruvic acid to produce the ketone containing
substrate Pyr-AAIVK. This peptide resembles the N-terminal
portion of dehydroepilancin 15X, with Dha at position 3 replaced
by Ala for simplicity. Incubation of Pyr-AAIVK with ElxO resulted
in a decrease in absorbance at 340 nmover timewith NADPHbut
not NADH. The reaction sample was also analyzed by liquid
chromatography mass spectrometry (LC-MS), and a new peak
with slightly shorter retention time and with m/z 573.4, corre-
sponding to Lac-AAIVK, was observed (Figure 3).
To determine the stereochemical configuration of the
N-terminal Lac, the two possible reaction products (D-Lac-
AAIVK and L-Lac-AAIVK) were synthesized by Fmoc-based
SPPS using D- or L-lactic acid during the last coupling step.
The enzymatic product of Pyr-AAIVK, after incubation with
His6-ElxO and NADPH, was combined with D-Lac-AAIVK or
L-Lac-AAIVK and analyzed by HPLC (Figures S2A–S2D). The
enzymatic product of His6-ElxO coeluted with D-Lac-AAIVK but
not with L-Lac-AAIVK, demonstrating that ElxO catalyzes the
formation of an N-terminal D-lactate ([R]-2-hydroxypropionate).Chemistry & Biology 18,Production of Epilancin 15X and Stereochemical
Characterization of the N-Terminal Lac Group
The production of lanthionine-containing polypeptide antibiotics
by staphylococci is highly dependent on the composition of the
media (Horner et al., 1989, 1990). To identify optimal conditions
for the production of epilancin 15X, a set of cultures was grown in
which the concentrations of meat extract, NaCl, and NH4Cl were
systematically varied. Analysis of culture supernatants for
bioactivity using an agar-diffusion assay with Staphylococcus
carnosus TM300 as indicator strain demonstrated that a medium
containing 10% Lab-Lemco meat extract, 2% NaCl, 20 mM
NH4Cl, 3% malt extract, and 0.4% Ca(OH)2 produced the high-
est concentration of epilancin 15X. Purification yielded about
3.0 mg of bacteriocin per liter of culture, compared with a yield
of 0.5 mg/l reported previously (Ekkelenkamp et al., 2005).
To determine the stereochemical configuration of the
N-terminal Lac in epilancin 15X, a sample of purified lantibiotic
was treated with trypsin, generating Lac-ADhaIVK among other
peptide fragments. The resulting peptide mixture and synthetic
samples of D-Lac-ADhaIVK and L-Lac-ADhaIVK, produced by
SPPS, were analyzed by LC-MS (Figures S2E–S2H). The
N-terminal proteolytic fragment of epilancin 15X coeluted with
D-Lac-ADhaIVK, confirming the stereochemical configuration of
the N-terminal Lac in epilancin 15X.
Cloning and Overexpression of elxP
The gene elxP was cloned initially into a pET28b vector to
generate an N-terminal hexahistidine fusion of ElxP (His6-ElxP).
However, attempts to overexpress the protein in E. coli were
unsuccessful, because the rate of growth of the host was greatly
reduced after induction with isopropyl b-D-1-thiogalactopyrano-
side (IPTG), suggesting that ElxP is toxic to the heterologous
host. To overcome toxicity problems and improve solubility,
elxPwas cloned into pHis6-MBP-ElxPwhich encodes for a fusion
protein containing an N-terminal pelB signal, followed by a hexa-
histidine tag for purification and amaltose-binding protein (MBP)
tag for solubility, separated from ElxP by a tobacco etch virus
(TEV) protease cleavage site (Figure S3A). Heterologous expres-
sion trials in E. coli Rosetta 2 cells using the plating method
(Suter-Crazzolara and Unsicker, 1995) afforded successful
production of His6-MBP-ElxP. The enzyme was purified by
IMACwith Ni2+, resulting in about 9mg of purified protein per liter
of cell culture. After treatment of His6-MBP-ElxP with TEV
protease and SDS-PAGE analysis, protein bands at about
34 kDa and 45 kDa, corresponding to ElxP (predicted mass of
34.3 kDa) and His6-MBP (predicted mass of 45.5 kDa), respec-
tively, were observed.
In Vitro Reconstitution of ElxP
Based on its amino acid sequence (Figure S1C), ElxP is a serine
protease that may cleave the leader peptide from the fully cy-
clized precursor peptide. Because modified ElxA was not avail-
able, linear His6-ElxA was tested as substrate, obtained by
expression from a pET28b vector in E. coli Rosetta 2 cells and
purification by IMAC with Ni2+ and subsequent HPLC. Linear
His6-ElxA was incubated with ElxP or His6-MBP-ElxP at pH
7.5. The reaction products were analyzed by MALDI-TOF MS,
confirming the formation of two proteolytic products in both
cases (Figure 4). The peak at m/z = 4865 corresponds to the857–867, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 859
Table 1. Open Reading Frame Analysis of the Epilancin 15X Gene Cluster Using BLASTp at the NCBI Website
Predicted
ORF
Number of
Amino Acids Protein Homology (GenBank Accession Number)a
Identity in the
Aligned Region
Expectation
Value
elxA 55 ElkA, epilancin K7 precursor peptide, S. epidermidis K17,
(AAA79236) (55 aa)
38/55 (69%) 7e-15
elxB 986 PepB, Pep5 dehydratase, S. epidermidis 5 (CAA90025) (967 aa) 327/994 (32%) 7e-104
elxC 402 PepC, Pep5 cyclase, S. epidermidis 5 (CAA90026) (398 aa) 142/379 (37%) 8e-56
elxO 248 EciO, oxidoreductase, S. epidermidis BN280 (CAA74346) (247 aa) (126/248) 50% 8e-64
elxP 297 EciP, epicidin 280 protease, S. epidermidis 5 (CAA74349) (300 aa) 123/286 (43%) 3e-48
elxT 573 PepT, Pep5 ABC transporter, S. epidermidis 5 (CAA90021) (571 aa) 354/571 (61%) 0.0
elxI1 72 Hypothetical protein SE2390, S. epidermidis ATCC 12228
(NP_765945) (76 aa)
43/65 (66%) 7e-18
elxI2 241 CAAX amino protease, S. epidermidis M23864:W1 (ZP_04817536)
(248 aa)
70/178 (39%) 8e-24
elxI3 71 Hypothetical protein, S. aureus subsp. aureus USA300_TCH959
(ZP_04865952) (75 aa)
43/71 (60%) 6e-17
orf1 177 Recombinase, S. aureus subsp. aureus TCH70 (ACZ58811) (182 aa) 154/176 (87%) 4e-85
orfA 261 Membrane-spanning protein, Staphylococcus hominis SK119
(ZP_04060547) (257 aa)
249/257 (96%) 1e-110
See also Figure S5.
a Results are from a BLASTp search of the GenBank protein database in January 2010.
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Biosynthesis of Epilancin 15XN-terminal hexahistidine-tagged leader peptide (residues 1 to
43) resulting from amide bond hydrolysis at the predicted
Gln(1) Ser(1) cleavage site, whereas the peak at m/z = 3316
corresponds to the C-terminal unmodified core peptide.Cloning and Coexpression of elxA and elxB
Based on bioinformatic analysis (Table 1), ElxB catalyzes the
dehydration of the precursor peptide ElxA. To confirm the role
of ElxB in epilancin 15X biosynthesis, the gene elxA and a
synthetic codon-optimized version of the gene elxBwere cloned
into a pRSFDuet-1 vector, as previously described for nisin (Shi
et al., 2011), to generate pHis6-ElxA.ElxB, which encodes for an
N-terminal hexahistidine fusion of ElxA (His6-ElxA) and for
untagged ElxB. Upon coexpression in E. coli BL21(DE3) cells,
followed by peptide purification and cleavage of the leader
region with His6-MBP-ElxP, a mixture of partially dehydrated
peptides was observed by MALDI-TOF MS (Figure S3B).
Attempts to obtain fully dehydrated peptide or to reconstitute
the enzymatic activity of ElxB in vitro were not successful.Incubation of Peptides with an Aminopeptidase
A sample of epilancin 15X was incubated with a commercially
available aminopeptidase from Aeromonas proteolytica. Inter-
estingly, no proteolysis products were observed by MALDI-
TOF MS, suggesting that the lactate group protects the
lantibiotic against degradation (Figure S4). To further evaluate
the possibility of the lactate group conferring stability against
aminopeptidases, the peptide Lac-AAIVKBBIKA (where B
stands for L-2-aminobutyric acid) mimicking the N-terminal
portion of dehydroepilancin 15X and the corresponding peptide
without the Lac group were generated. The two peptides were
incubated with the aminopeptidase from A. proteolytica, fol-
lowed by analysis by electrospray ionization mass spectrometry
(ESI-MS) (Figure 5A). Whereas the peptide lacking the lactate860 Chemistry & Biology 18, 857–867, July 29, 2011 ª2011 Elsevier Lgroup was completely degraded, the peptide containing the
N-terminal lactate was detected intact.
In contrast, when lacticin 481 (Figure 5B), a lantibiotic lacking
N-terminal modifications, was incubated with the aminopepti-
dase under similar conditions, a peptide missing the first seven
N-terminal residues was obtained as the main product (Fig-
ure 5C). Thus, the aminopeptidase was able to remove
N-terminal unmodified amino acids with the exception of the
His preceding the first MeLan ring that protects the lantibiotic
from additional proteolysis. Lacticin 481(2–27) and lacticin
481(3–27) were also observed, suggesting that the GG motif at
position 2 is processed at a lower rate and may partially protect
the bacteriocin against the action of aminopeptidases. The pro-
teolyzed lacticin 481 and control samples were tested by agar-
diffusion assays using the indicator strain Lactococcus lactis
subsp. cremoris HP (Figure 5D), demonstrating a decrease in
antibacterial activity of the proteolyzed peptides. These results
are consistent with previous reports that have shown that the
linear N-terminal portion of lacticin 481 is important for bioac-
tivity (Levengood et al., 2009; Uguen et al., 2005).
DISCUSSION
Lantibiotics are produced from ribosomally synthesized linear
precursor peptides that consist of an N-terminal leader region
and a C-terminal core peptide. The mature lantibiotic is gener-
ated from the core peptide after several posttranslational modi-
fications. The reactions involved in the formation of the charac-
teristic Lan and MeLan rings have been investigated (Goto
et al., 2010; Li et al., 2006; Xie et al., 2004), but only a few
enzymes introducing other posttranslational modifications
have been studied (Kupke et al., 1994; Majer et al., 2002; Mu¨ller
et al., 2010). This investigation focused on the mechanism of
formation of N-terminal lactate groups and on the enzymatic
cleavage of the leader peptide.td All rights reserved
Figure 3. Enzymatic Assay of His6-ElxO with Pyr-AAIVK
Shown are single-ion chromatograms at m/z = 573.4, corresponding to the
expected [M+H]+ ion for Lac-AAIVK, for the reaction mixture (solid line) and
a control sample (dashed line). The peak at 16 min observed in the reaction
sample but not in the control confirms the enzymatic reduction of the peptide.
The peak at 17 min in the control sample is derived from higher-molecular
weight isotopologues of the substrate (monoisotopic m/z = 571.4). See also
Figure S2.
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Biosynthesis of Epilancin 15XThe epilancin 15X gene cluster contains five genes involved in
biosynthesis (elxABCOP), one gene involved in the export of the
mature peptide (elxT), and three genes potentially involved in
immunity (elxI1, elxI2, and elxI3) (Table 1; Figure 2). The cluster
organization resembles that of the lantibiotics Pep5 (Meyer
et al., 1995) and epicidin 280 (Heidrich et al., 1998) produced
by different strains of S. epidermidis, suggesting that these clus-
ters have evolved from a common ancestor. The predicted
peptide ElxA has high amino acid sequence similarity to the epi-
lancinK7precursor peptideElkA (van deKampet al., 1995b) (Fig-
ure S1A). ElxA contains an N-terminal leader sequence of 24
amino acids and a C-terminal core peptide region composed of
31 amino acids, as predicted from the chemical structure of epi-
lancin 15X. The leader region also contains the conserved motif
F-(N/D)-L-(N/D/E) and a Pro at position2 that are characteristic
of class I lantibiotics (Figure S1A) (van der Meer et al., 1994).Figure 4. MALDI-TOF MS Analysis of Proteolytic Digestion of His6-Elx
Similar results were obtained when ElxP was used.
(A) Analysis of His6-ElxA (calculated mass = 8162.3 Da) after incubation without
(B) Analysis of peptidemixture after incubationwith enzyme under the same condi
and to the core peptide (calculated mass = 3316.0 Da) are observed.
See also Figure S3.
Chemistry & Biology 18,Downstream of elxA, an ORF designated elxP was identified.
The encoded protein ElxP possesses high amino acid sequence
similarity to EciP, the protease involved in the biosynthesis of
epicidin 280 (Heidrich et al., 1998), and to other subtilisin-like
serine proteases. Importantly, the residues of the predicted
catalytic triad and oxyanion hole (Asp27, His62, Ser240, and
Asn154) are conserved in ElxP (Figure S1C). The lack of an
N-terminal sec-signal sequence and a C-terminal cell wall
anchor sequence (LPXTG) suggests that ElxP is localized inside
the cytoplasm, possibly as part of a membrane-bound biosyn-
thetic complex. Thus, ElxP likely removes the leader peptide
before the mature peptide is transported outside the cell, in
contrast to other class I lantibiotic proteases, such as NisP or
EpiP, that are located extracellularly and remove the leader
region once the peptide has been secreted (Figure S1C).
In a previous attempt to study LanP proteases, an E. coli host
carrying a plasmid encoding for NisP was able to express the
protease at low concentrations based on SDS-PAGE analysis
using [35S]Met (van der Meer et al., 1993). Although NisP was
not purified, the E. coli cell extracts cleaved the nisin A cyclized
precursor peptide, producing a biologically active compound
(van der Meer et al., 1993). Additional in vivo studies indicated
that NisP is able to cleave the leader region only from fully pro-
cessed precursor peptide but not from uncyclized dehydrated
or unmodified NisA (Kuipers et al., 2004). Similar results were ob-
tained from in vivo studies of the lantibiotic Pep5 (Meyer et al.,
1995). In contrast, culture supernatants of S. carnosus TM300
expressing EpiP processed unmodified EpiA to the expected
proteolytic products (Geissler et al., 1996). In the present study,
ElxP was successfully expressed in E. coli and its enzymatic
activity was reconstituted in vitro. The protease was able to
process unmodified His6-ElxA, indicating that neither the Lan/
MeLan ring nor the dehydrated residues, including Dha at posi-
tion 1, are strictly required for enzyme recognition and proteo-
lytic processing.
Downstream of elxP, an ORF designated elxB encodes
a protein with homology to PepB, the enzyme that catalyzes
the dehydration of Ser or Thr residues in the Pep5 precursorA by His6-MBP-ElxP
enzyme in reaction buffer.
tions. Peaks corresponding to the leader peptide (calculatedmass = 4864.3 Da)
857–867, July 29, 2011 ª2011 Elsevier Ltd All rights reserved 861
Figure 5. Degradation of Peptides by A. proteolytica Aminopeptidase
(A) ESI-MS analysis of the peptides Lac-AAIVKBBIKA (top left) and AAIVKBBIKA (bottom) after incubation with A. proteolytica aminopeptidase. Only the peptide
lacking the Lac group was completely degraded by the aminopeptidase (bottom) compared with a control sample lacking enzyme (top right). The observedm/z
peaks correspond to the [M+2H]2+ ions.
(B) Structure of the lantibiotic lacticin 481, using the shorthand notation described in Figure 1.
(C) MALDI-TOF MS analysis of lacticin 481 (calculated m/z = 2902) after incubation with A. proteolytica aminopeptidase (top spectrum) and a control sample
lacking peptidase (bottom spectrum). Peaks corresponding to lacticin(8–27) (calculated m/z = 2304), lacticin(2–27) (calculated m/z = 2774), and lacticin(3–27)
(calculated m/z = 2717) were observed.
(D) Agar-diffusion bioactivity assay of lacticin 481 after treatment with the peptidase (spot 1) and a control sample without peptidase (spot 2) using L. lactis subsp.
cremoris HP as indicator strain. A control sample containing the peptidase but no lantibiotic was also tested (spot 3).
See also Figure S4.
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Biosynthesis of Epilancin 15Xpeptide (Meyer et al., 1995). Analysis of ElxB with SignalP 3.0
(Emanuelsson et al., 2007) suggests that this protein may
contain an N-terminal cell membrane anchor signal. The activity
of ElxB homologs of class I lantibiotics has never been reconsti-862 Chemistry & Biology 18, 857–867, July 29, 2011 ª2011 Elsevier Ltuted in vitro (Xie et al., 2002), and the cofactors or metals
involved in catalysis are currently unknown. In this work, we
were also unable to reconstitute ElxB activity in vitro. However,
coexpression of His6-ElxA and ElxB in E. coli producedtd All rights reserved
Figure 6. Proposed Biosynthetic Steps Involved in
the Production of Epilancin 15X and Its N-Terminal
D-Lactate Group
(A) Posttranslational modifications converting ElxA into
epilancin 15X. Note that it is not known whether dehy-
dration is completed before cyclization commences.
(B) Conversion of the Dha in position 1 to (R)-lactate.
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Biosynthesis of Epilancin 15Xa partially dehydrated peptide, confirming the role of the protein
in the biosynthesis of epilancin 15X. Closer inspection of the
ElxB sequence indicates that it contains an almost conserved
Walker A motif (GXXXXGKT/S: GLLENWKT) and a conserved
Walker B motif (hhhhD: IIFPD, where h stands for hydrophobic
residue) (Figure S1B). In addition, the three potential binding
sites characteristic of GTP-binding proteins are also present
(DXXG: DFLG; NKXD: NTID/NDID/NLND/NRND; SAX: SAT)
(Kjeldgaard et al., 1996), suggesting that GTP or another nucle-
otide may be required for dehydration by LanB proteins, similar
to class II–IV lanthionine synthetases (Chatterjee et al., 2005a;
Goto et al., 2010; Mu¨ller et al., 2010; Xie et al., 2004). The
ORF elxC encodes a protein with high amino acid sequence
similarity to PepC, the cyclase responsible for Lan and MeLan
ring formation in Pep5 (Meyer et al., 1995). Additionally, ElxCChemistry & Biology 18, 857–867, July 29contains the conserved residues comprising
a zinc ion binding site (Cys269, Cys318, and
His319) and the residues involved in acid-
base catalysis (His205 and Asp142) that are
characteristic of this family of proteins (Li and
van der Donk, 2007; Li et al., 2006).
Based on the experimental results and on bi-
oinformatic analysis, the first steps of epilancin
15X biosynthesis can be postulated (Figure 6A).
The precursor peptide ElxA is modified by the
dehydratase ElxB and the cyclase ElxC to
produce the crosslinked peptide. Then, the
leader peptide is removed by the protease
ElxP, producing an N-terminal enamine (Dha)
present in equilibrium with the corresponding
imine that can be hydrolyzed to produce dehy-
droepilancin 15X (Figure 6B). Although enamine
hydrolysis is fast (Sollenberger and Martin,
1970), enzymatic assistance (e.g., by ElxP)
cannot be ruled out at present. The reduction
of the N-terminal ketone to the respective
alcohol will complete the synthesis of mature
epilancin 15X.
The ORF elxO encodes a protein with
homology to EciO, an oxidoreductase hypothe-
sized to be involved in the reduction of pyruvate
to lactate in the biosynthesis of epicidin 280
(Heidrich et al., 1998). ElxO contains a predicted
N-terminal NAD(P)(H) binding site (GXXGXG:
GGFKGIGK) and the catalytic triad residues
(Ser139, Tyr152, and Lys156) of the SDR protein
superfamily (Figure S1D) (Jo¨rnvall et al., 1995;
Tanaka et al., 2001). The absence of the ‘‘prox-
imal Asp residue’’ (Ser33 in ElxO) and the pres-
ence of the ‘‘proximal basic residues’’ (Lys12and Arg34), responsible for cofactor specificity, correctly pre-
dicted that ElxO is an NADPH-dependent enzyme and that it
belongs to the cP3 subfamily (Kallberg et al., 2002; Tanaka
et al., 2001). The stereochemical course of the reaction estab-
lished here allows assignment of the configuration of the
N-terminal lactate group of epilancin 15X as (R). Because His6-
ElxO was able to reduce a hexamer peptide, the thioether rings
or other structural motifs in dehydroepilancin 15X are not
required for enzyme recognition.
The ORF elxT encodes a putative protein with homology to
PepT (Meyer et al., 1995). The C-terminal domain of ElxT
contains an ATP binding site characterized by the conserved
Walker A motif (GXXXXGKT/S: GPSGAGKT) or P loop, the
Walker B motif (hhhhD: ILLLD), and the C motif or ‘‘signature’’
motif (LSGGQ) specific to ABC transporters (Figure S1E)., 2011 ª2011 Elsevier Ltd All rights reserved 863
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et al., 2007) indicates that its N-terminal portion contains six
transmembrane helices. Thus, ElxT is likely involved in lantibiotic
secretion.
Epilancin 15X has potent activity against staphylococci,
including strains of S. epidermidis (Verhoef et al., 2005), suggest-
ing that the producer strain must have an effective self-resis-
tance mechanism. Such immunity is particularly important for
epilancin 15X because it is activated by leader peptide removal
within the cytoplasm, unlike most lantibiotics, for which leader
peptide cleavage occurs after or concomitant with secretion.
Downstream of elxC, the three ORFs elxI1, elxI2, and elxI3
were identified. The genes elxI1 and elxI3 potentially encode
for 72 and 71 amino acid paralog peptides (47% identity) with
no sequence homology to previously characterized proteins.
Analysis by TMHMM 2.0 (Emanuelsson et al., 2007) indicates
that ElxI1 and ElxI3 contain two highly hydrophobic a-helical
domains followed by strongly hydrophilic C-terminal segments
(Figure S5). Thus, although ElxI1 and ElxI3 contain no signal
peptides, these small proteins may be localized at the cyto-
plasmic membrane. A similar pattern of helical domains followed
by a hydrophilic region is found in small proteins encoded by the
gene clusters of the closely related lantibiotics Pep5 (Hoffmann
et al., 2004) and epicidin 280 (Heidrich et al., 1998), the structur-
ally unrelated lactosin S (Skaugen et al., 1997), the nonlantibiotic
bacteriocin divergicin A (Worobo et al., 1995), and the circular
bacteriocins AS-48, acidocin B, butyrivibriocin AR10, and circu-
larin A (Maqueda et al., 2008). In the case of Pep5, the protein
was designated PepI and was shown to be a determinant for
self-resistance of the producer strain (Reis et al., 1994). Interest-
ingly, in all of the lantibiotics mentioned above, intracellular
peptidases remove the leader peptide and the mature bacte-
riocin is produced inside the cell. PepI has been suggested to
bind to a (currently unknown) target molecule, avoiding docking
of the lantibiotic Pep5 onto the target (Hoffmann et al., 2004).
Despite the absence of significant sequence homology between
PepI and ElxI1/3, the topological similarity suggests that these
peptides may protect the host organism in a similar fashion
(Figure S5).
Finally, the putative immunity protein ElxI2 has high sequence
similarity to Abi proteins, membrane-bound metalloproteases
that are involved in self-resistance to plantaricin EF and JK,
sakacin 23K, or streptolysin S (Datta et al., 2005; Kjos et al.,
2010). ElxI2 is predicted to contain seven transmembrane
domains, including the final four a helices that form the Abi
domain (Figure S1F). Three highly conserved motifs (EEXXXR:
EEILYR; FXXXH: FSLIH; and His226) likely constitute the active
site of the protease (Pei and Grishin, 2001). Thus, ElxI2 may
protect the host against the bacteriocin by direct degradation
of the peptide.
Whether elxI1, elxI2, and elxI3 are part of the cluster and are
involved in the immunity mechanism is at present not certain.
Closer analysis of the noncoding sequences upstream of elxC,
elxI1, and elxI2 suggests the presence of only one relevant
inverted repeat between elxC and elxI1, partially overlapping
elxC, and with a calculated free energy of 10.2 kcal/mol. This
repeat may work as a weak rho-independent transcriptional
terminator that allows partial readthrough, indicating that elxC
and elxI1–3 may be part of a single operon and the same gene864 Chemistry & Biology 18, 857–867, July 29, 2011 ª2011 Elsevier Lcluster. Downstream of elxI3, a noncoding region of 329 bp is
followed by the ORF orfA in a different operon that encodes
a putative ABC transporter with no sequence homology to any
known lantibiotic proteins but with significant homology to trans-
porters from staphylococci. Thus, OrfA is not likely to be related
to epilancin 15X biosynthesis. Flanking the putative epilancin
15X gene cluster on the other side, an ORF designated orf1
was identified. Orf1 is a putative recombinase, not likely to be
involved in epilancin 15X biosynthesis, transport, or immunity.
Thus, the epilancin 15X cluster likely spans a 9.2 kb region in
the S. epidermidis 15X154 genome and includes the genes
from elxO to elxI3 (Figure 2).
The role of the N-terminal Lac in epilancin 15X is currently
unknown. However, N-terminal modifications are common in
lantibiotics and include (methyl)lanthionines, disulfides, pyruvate
and lactate groups, 2-oxobutyrate groups, and acylations. The
N-terminal disulfide in Hala (one of the two peptides in halodur-
acin) was shown not to be important for antimicrobial activity but
to protect the peptide from exoproteases (Cooper et al., 2008;
McClerren et al., 2006). Similarly, the N-terminal lanthionine in
lacticin 3147 A1 is not required for antimicrobial activity (Cotter
et al., 2006), but may protect lacticin 3147 A1 from proteolysis.
A similar role for the N-terminal lactate group in epilancin 15X
is supported in this study.SIGNIFICANCE
The recently discovered lantibiotic epilancin 15X produced
by S. epidermidis 15X154 has potent antimicrobial activity
against drug-resistant strains of S. aureus. Epilancin 15X is
structurally simple compared with other lantibiotics and
yet is very active. The compound contains an unusual
N-terminal D-lactate group that could be essential for biolog-
ical activity. This study demonstrates that this moiety
confers stability against proteolytic degradation by amino-
peptidases, a feature thatmay be applied for the engineering
of novel lantibiotics with enhanced antibacterial activities or
different spectra of action. Furthermore, the gene cluster for
epilancin 15X was determined and the enzymatic activities
of the dehydratase, protease, and oxidoreductase involved
in the biosynthesis were demonstrated in vitro or in vivo.EXPERIMENTAL PROCEDURES
Genomic Library Construction, Screening, and DNA Sequencing
For all primer sequences and microorganisms, see Tables S1 and S2.
Genomic DNA was obtained as described in Supplemental Experimental
Procedures and partially digested with Sau3A1 (New England Biolabs) in the
presence of RNase A (Sigma-Aldrich) using serial dilutions of the enzyme.
The DNA solutions were analyzed by field inversion gel electrophoresis on
a 1% agarose/TBE gel and the fraction containing 20–60 kb DNA fragments
was treated with shrimp alkaline phosphatase (Roche Diagnostics).
Cosmid pJK050 was digestedwith NheI (New England Biolabs), treated with
shrimp alkaline phosphatase, and purified. The cosmid was further treated
with BamHI (Invitrogen). Digested pJK050 and genomic DNA were ligated
with T4 DNA ligase (New England Biolabs) and cosmid constructs were pack-
aged into lambda phage with a MaxPlax Lambda Packaging Extract kit
(Epicenter) according to the manufacturer’s protocol, followed by transfection
of E. coli WM4489. Library clones were screened by PCR for the elxA gene
using forward primer elxA-F1 and reverse primer elxA-R2, or for the elxCtd All rights reserved
Chemistry & Biology
Biosynthesis of Epilancin 15Xgene with forward primer elxC-596F and reverse primer elxC-781R, Taq poly-
merase (Invitrogen), and 13 PCR premix A (Epicenter).
Plasmid pAE5 was digested with BglII, and the 1084 bp fragment to be used
as a transposon was gel purified. For each positive fosmid, the fragment and
the positive fosmidweremixed and treatedwithMuA transposase (Finnzymes)
and the dialyzed DNA was used to transform E. coli WM4489. Sets of 192
clones were sequenced from the ends of the transposon insert using primers
seqaetf and seqaetr at the Keck Center for Comparative and Functional Geno-
mics at the University of Illinois at Urbana-Champaign. Using S. epidermidis
15X154 as template, the specific primers elxBgapF and elxCgapR were
used to amplify and sequence a DNA fragment of 1.2 kb, closing the sequence
gap between the fosmids.
Construction of Plasmids pHis6-ElxO, pHis6-ElxA,
and pHis6-MBP-ElxP
The gene elxO was amplified by PCR from S. epidermidis 15X154 genomic
DNA using a forward primer containing an NheI restriction site (elxO.NheI.F)
and a reverse primer containing an XhoI site (elxO.XhoI.R). The PCR product
and the vector pET28b (Novagen) were digested with restriction endonucle-
ases NheI and XhoI (Invitrogen) and ligated using T4 DNA ligase (New England
Biolabs) to produce the plasmid pHis6-ElxO.
The gene elxA was amplified by PCR from S. epidermidis 15X154 genomic
DNA using a forward primer containing an NdeI restriction site (elxA.NdeI.F)
and a reverse primer containing an EcoRI site (elxA.EcoRI.R). The PCRproduct
and the vector pET28b (Novagen) were digested with restriction endonucle-
ases NdeI and EcoRI (Invitrogen) and ligated using T4 DNA ligase (New
England Biolabs) to produce the plasmid pHis6-ElxA.
The gene elxP was amplified by PCR from S. epidermidis 15X154 genomic
DNA using a forward primer (elxP.28MBP.F) and a reverse primer
(elxP.28MBP.R). The PCR product contained annealing regions to a modified
pET28b vector (Novagen) that encodes for a fusion pelB, hexahistidine-tagged
MBP. The purified PCR product was used as a primer to amplify the vector
using Phusion Hot Start DNA polymerase (New England Biolabs), followed
by treatment with DpnI (New England Biolabs) before transformation of
E. coli DH5a cells to generate the plasmid pHis6-MBP-ElxP that encodes for
ElxP fused at its N terminus to a TEV protease cleavage site, an MBP tag,
a hexahistidine tag, and a pelB signal peptide (Figure S3A). The correct
sequences of the inserts were confirmed by sequencing at the Keck Center
at the University of Illinois at Urbana-Champaign. E. coli BL21(DE3) Rosetta
2 cells were transformed with pHis6-ElxO, pHis6-ElxA, or pHis6-MBP-ElxP,
and the proteins were overexpressed and purified by IMAC (Supplemental
Information).
His6-ElxO and ElxP Activity Assays
His6-ElxO (10 mM) and the peptide Pyr-AAIVK (1 mM) generated by Fmoc-
based SPPS (Supplemental Information) were incubated with NADPH
(1 mM) in assay buffer (100 mM HEPES [pH 7.5]) at room temperature for
6 hr. Reaction progress was monitored by UV-vis spectrophotometry,
measuring the disappearance of the NADPH peak at 340 nm. Formation of
reduced peptide was confirmed by LC-MS using an Agilent 1200 instrument
equipped with a single-quadrupole multimode ESI/atmospheric pressure
chemical ionization ion source mass spectrometry detector (Agilent) and a
Synergi Fusion-RP column (4.6 mm i.d. 3 150 mm length; Phenomenex).
ElxP or His6-MBP-ElxP (5 mM) and purified His6-ElxA (Li et al., 2009) (50 mM)
were incubated in the presence of an assay buffer (50 mM HEPES, [pH 7.5])
at room temperature for 2–3 hr. A control sample lacking enzyme was incu-
bated under the same conditions. Cleavage of the peptide in the reaction
sample was confirmed by MALDI-TOF MS as described above.
Production and Purification of Epilancin 15X
A medium composed of Lab-Lemco meat extract (10%; Oxoid), malt extract
(3%; Becton Dickinson), ammonium chloride (20 mM), Ca(OH)2 (0.4%), and
NaCl (2%) was inoculated with an overnight preculture of S. epidermidis
15X154 in LB broth (1/100 dilution). Cells were incubated at 37C with shaking
for 12 hr and harvested by centrifugation. The supernatant was filtered through
a 0.22 mm pore size filter and heated at 80C for 1 hr to deactivate proteases.
Solid (NH4)2SO4was added to the culture supernatant to reach 80%saturation
at 4C and stirred for 4 hr followed by centrifugation. The pellet was resus-Chemistry & Biology 18,pended in water and loaded onto a Vydac C4 reverse-phase solid-phase
extraction column (214SPE1000; Discovery Sciences). The column was
washed with 25% acetonitrile in ammonium acetate buffer (20 mM, pH 5.0)
to remove impurities and the peptide was eluted with 80% methanol in 0.1%
trifluoroacetic acid (TFA)/water. The lantibiotic was further purified by HPLC
using an Agilent 1200 instrument (Agilent) equipped with a Vydac 214TP54
C4 reverse-phase column (4.6 mm i.d. 3 250 mm L; Discovery Sciences). A
gradient of 50%–60% B (0.1% TFA in methanol) in A (0.1% TFA in water)
over 50 min was used. The fractions corresponding to the major peak were
collected. Analysis of the final product by ESI-MS on a Waters Synapt instru-
ment showed a mass of 3172.6817 Da (calculated monoisotopic mass of epi-
lancin 15X: 3172.6977 Da).
Incubation of Peptides with A. proteolytica Aminopeptidase
Epilancin 15X was incubated with A. proteolytica aminopeptidase (10 U/ml;
Sigma-Aldrich) in assay buffer (40 mM Tris-HCl [pH 8.0]) at room temperature
for 24 hr. Samples containing purified lacticin 481 with or without protease
were incubated under the same conditions for 12 hr. The reaction products
were analyzed by MALDI-TOF or ESI-MS/MS and tested by agar-diffusion
bioactivity assays using M17 agar medium supplemented with 0.5% glucose
and L. lactis subsp. cremoris HP as indicator strain.
The peptide Lac-AAIVKBBIKA, generated from Pyr-AAIVKBBIKA enzymat-
ically with His6-ElxO as described above, and the control peptide AAIVKBBIKA
were also incubated with the peptidase under similar conditions for 6 hr. The
peptides were then purified by solid-phase extraction using Discovery DSC-
18 columns (1 ml, 50 mg; Supelco) and 0.1% formic acid in water or 0.1%
formic acid in 60% acetonitrile as washing and eluting solvents, respectively,
and analyzed by ESI-MS using a ZMD quadrupole instrument (Waters) at the
Mass Spectrometry Laboratory of the University of Illinois at Urbana-
Champaign.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2011.05.007.
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